1. Oblique Back-illumination Microscopy Jerome Mertz June 15, 2012

2. 600μm field-of-view with 6.5μm resolution 240μm field-of-view with 2.5μm resolution No labeling or contrast required Video rate Oblique Back-illumination Microscopy (OBM) Breakthrough imaging allows DIC-like images in thick samples

3. OBM offers superior imaging and high clinical impact in a simple, robust, and cost-effective platform Superior imaging capabilities with high clinical impact Exquisite high resolution phase images (DIC-like) of in vivo tissue morphology Simultaneous phase and amplitude microscopy with tissue imaging depth of 60-100μm – improves diagnostic imaging in thick tissue – applications in endoscopy Works at video rate with a standard camera Simple, robust, cost effective, and safe Add-on to current microscopes or endomicroscopes, with no moving parts Noninvasive, no tissue labeling required Illuminated using LEDs rather than expensive and unsafe lasers

4. Both research and clinical applications are possible with OBM $3B US Microscope Market in 2011 with 6% CAGR through 2015 1 Several Established Players: Leica, Carl Zeiss, Olympus, etc 790 Potential Target Labs in US 2 GI Endoscopy –> 10 MM Procedures / year –Colorectal, Gall, Esophageal Blood flow analysis in plastic / reconstructive surgery –>1MM surgeries per year Bladder imaging Research Applications Clinical Applications 3 1.Jon Groberg, Dane Leone, CFA, “Danaher: BEC is the key to continued success”, Macquarie (USA) Equities Research, 16 Aug 2011 2.Source: http://www.lltechimaging.com/http://www.lltechimaging.com/ 3.Source: Mauna Kea Investor Presentation, published June 2011

5. Colorectal Screenings GI screening offers a compelling opportunity for OBM Barrett’s Esophagus 3.1 MM colorectal screenings in US annually High percentage of biopsied polyps are benign Strong market opportunity for technologies that aid in biopsy site determination > 1 MM screenings in US annually American Gastroenterological Assoc. recently increased recommended screening schedule for high risk patients 85% mortality rate for Esophageal cancer (BE increases cancer risk)

6. OBM combines high resolution imaging with tissue depth, wide field-of-view and video capabilities OBMOCT 1 Confocal fluorescence Endomicroscopy 2 Technology 2.5 / 6.53.51 - 3.5 Lateral Resolution (μm) 61.83 - 8 Axial Resolution (μm) 0 - 801005 - 100 Imaging Depth (μm) 240 / 600 1.5 x 1.5 mm (scanning) 240 / 400 Field of View (μm) 1. Optical Coherence Tomography – data points based on lltech Light-CT 2. Confocal Laser Endomicroscopy – data points based on various CellVizio models 17.51 12 (200 optional) Frame Rate (Hz)

7. Rigid endoscope market exceeds $500M annually; Karl Storz is the market leader Market Size (2010): $529M WW, 4% CAGR $176M US, 4% CAGR Laparoscopic, Hysteroscopic uses Source: “Rigid Endoscopes - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017”, Global Data, 31 May 2011

8. In vivo Imaging Technologies TechnologyCompanyProductUnit CostTarget Areas OCT St. Jude Medical Ilumien (OCT + FFR) Unknown Stent Placement, Vulnerable Plaque ID OPS Lekam Medical Ltd CytoscanUnknown Microcirculation (possibly no sales since 2004) LIFSpectraSciencewavSTATUnknownColorectal/esophageal Cancer Optical Spectroscopy Guided Therapeutics LuViva $18,500 1 Cervical Cancer Circulation Imaging NovadaqPinPoint$75,000 4 Lung, Colectomy, Lap Chole, MIS CLE Mauna Kea Technologies (via Leica) Cellvizio$160,000 2 Barret's, Colorectal, Chole Multispectral Imaging Mela SciencesMelaFind$35,000 3 Melanoma 1. Thomson Reuters Streetevents, “Edited Transcript: GTHP.OB-Q4 2011 Guided Therapeutics Inc. Earnings Conference Call”, 29 March 2012, 3:00PM GMT 2. Source: Mauna Kea Investor Presentation, published June 2011 3. Josh Jennings, M.D., Denis Kelleher, Ian Sanderson, Doug Schenkel, “Mela Sciences – Initiating with Outperform (1)”, Cowen and Company, 23 May 2012 4. Matt Miksic, Sachin Kulharni, Young Li, “ Novadaq: Overweight”, PiperJaffray, Company Note, 16 April 2012